News and Events
Celebrating CCR Careers: R. Andrew Byrd, Ph.D.
32 years ago, R. Andrew Byrd, Ph.D., came to NCI Frederick to study the foundational biophysics of cancer. After an extensive career developing and utilizing nuclear magnetic resonance (NMR) spectroscopy methods to determine protein structures and mechanistic insight, he has announced his retirement.
Read More
Researchers use artificial intelligence to tease apart subtypes of glioma
A new machine learning algorithm can dig deep into spectral data of brain tumor tissue to reveal genetic mutations, DNA methylation and even the fat content of gliomas. This research advance could help scientists better classify — and one day better treat — brain cancer.
Read More
Chengkai Dai appointed to Senior Investigator at CCR
The CCR community congratulates Chengkai Dai, Ph.D., who has been appointed Senior Investigator in the Mouse Cancer Genetics Program. Dai’s laboratory is a pioneer in the field of proteomic instability of cancer. His ongoing research focuses on the molecular mechanisms through which proteomic instability may affect genomic stability, cell invasion and autophagy, areas which hold promise to unveil new molecular pathways that could be targeted in cancer therapy.
Read More
Celebrating CCR Careers: Glenn Merlino, Ph.D.
Since first arriving at NCI in 1980, Glenn Merlino, Ph.D., has had a keen interest in unraveling the mechanistic underpinnings of cancer and how this knowledge could be used to improve patient care. Now, after decades of impactful research and mentorship, he is announcing his retirement.
Read More
Peter Pinto awarded the AAGUS Barringer Medal
Peter A. Pinto, M.D., Senior Investigator in the Urologic Oncology Branch, was awarded the Barringer Medal by the American Association of Genitourinary Surgeons (AAGUS). The AAGUS is an association of leading academic urologists from the United States, Canada and around the world, dedicated to the study of diseases of the genitourinary system.
Read More
Clinical trial researching immunotherapy for bladder cancer
A trial led by Andrea B. Apolo, M.D., Senior Investigator in the Genitourinary Malignancies Branch, is studying combination drug therapy and immunotherapy for bladder and urinary tract cancer.
Read More
Aligned Blog: Knowledge is Power: The Value and Importance of Genetic Counseling
This year's U.S. Food and Drug Administration's 4th Annual National Black Family Cancer Awareness Week falls from June 13-19, 2024. In honor of the theme, "Engaging Generations," we invited Michaela Taylor, M.S., CGC, Cancer Genetics Counselor in the Genetics Branch to write about the value of genetic counseling for Black and African American people and how broaching this sometimes difficult topic can lead to empowerment.
Read More
NIH scientists develop AI tool to predict how cancer patients will respond to immunotherapy
In a proof-of-concept study, CCR researchers developed an artificial intelligence (AI) tool that uses routine clinical data to predict whether someone’s cancer will respond to immune checkpoint inhibitors. The machine-learning model may help doctors determine if these immunotherapy drugs are effective for treating a patient’s cancer. The study, published June 3, 2024, in Nature Cancer, was led by Eytan Ruppin, M.D., Ph.D., Chief of the Cancer Data Science Laboratory, and collaborators at Memorial Sloan Kettering Cancer Center in New York.
Read More
Clinical trial researching combination immunotherapy for colorectal cancer
A trial led by Jason M. Redman, M.D., Assistant Research Physician in the Center for Immuno-Oncology, is studying combination immunotherapy for colorectal cancer.
Read More
Celebrating CCR Careers: David D. Roberts, Ph.D.
David D. Roberts, Ph.D., a biochemist who identified a new pathway that controls cell responses to stress and developed approaches to improve cancer therapy by shutting it down, announces his retirement from the NCI.
Read More
Clinical trial researching drug therapy for neuroendocrine neoplasms
A trial led by Jaydira Del Rivero, M.D., Associate Research Physician in the Developmental Therapeutics Branch, is studying a new drug for neuroendocrine neoplasms, a group of rare cancers.
Read More